BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.-论文-万方医学网

第一作者： Matthew,Mistry

第一单位： Matthew Mistry, Nataliya Zhukova, Daniele Merico, Rahul Krishnatry, Mary Shago, James Stavropoulos, Noa Alon, Peter N. Ray, Vilma Navickiene, Joshua Mangerel, Marc Remke, Vijay Ramaswamy, Ana Guerreiro Stucklin, Martin Li, Edwin J. Young, Cindy Zhang, Pedro Castelo-Branco, Doua Bakry, Suzanne Laughlin, James T. Rutka, Peter B. Dirks, Michael D. Taylor, Mark Greenberg, David Malkin, Annie Huang, Eric Bouffet, Cynthia E. Hawkins, and Uri Tabori; The Hospital for Sick Children; Matthew Mistry, Patricia Rakopoulos, Rahul Krishnatry, Joshua Mangerel, Pawel Buczkowicz, Ana Guerreiro Stucklin, Doua Bakry, Adam Shlien, Mark Greenberg, David Malkin, Annie Huang, Eric Bouffet, Cynthia E. Hawkins, and Uri Tabori, University of Toronto; Jason D. Pole, Pediatric Oncology Group of Ontario, Toronto, Ontario; Jennifer Chan, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada; Pedro Castelo-Branco, Universidade do Algarve, Faro, Portugal; Keith L. Ligon, Dana-Farber/Boston Children's Cancer Center, Boston, MA.

作者： Matthew,Mistry ^[1] ; Nataliya,Zhukova ^[1] ; Daniele,Merico ^[1] ; Patricia,Rakopoulos ^[1] ; Rahul,Krishnatry ^[1] ; Mary,Shago ^[1] ; James,Stavropoulos ^[1] ; Noa,Alon ^[1] ; Jason D,Pole ^[1] ; Peter N,Ray ^[1] ; Vilma,Navickiene ^[1] ; Joshua,Mangerel ^[1] ; Marc,Remke ^[1] ; Pawel,Buczkowicz ^[1] ; Vijay,Ramaswamy ^[1] ; Ana,Guerreiro Stucklin ^[1] ; Martin,Li ^[1] ; Edwin J,Young ^[1] ; Cindy,Zhang ^[1] ; Pedro,Castelo-Branco ^[1] ; Doua,Bakry ^[1] ; Suzanne,Laughlin ^[1] ; Adam,Shlien ^[1] ; Jennifer,Chan ^[1] ; Keith L,Ligon ^[1] ; James T,Rutka ^[1] ; Peter B,Dirks ^[1] ; Michael D,Taylor ^[1] ; Mark,Greenberg ^[1] ; David,Malkin ^[1] ; Annie,Huang ^[1] ; Eric,Bouffet ^[1] ; Cynthia E,Hawkins ^[1] ; Uri,Tabori ^[2]

作者单位： Matthew Mistry, Nataliya Zhukova, Daniele Merico, Rahul Krishnatry, Mary Shago, James Stavropoulos, Noa Alon, Peter N. Ray, Vilma Navickiene, Joshua Mangerel, Marc Remke, Vijay Ramaswamy, Ana Guerreiro Stucklin, Martin Li, Edwin J. Young, Cindy Zhang, Pedro Castelo-Branco, Doua Bakry, Suzanne Laughlin, James T. Rutka, Peter B. Dirks, Michael D. Taylor, Mark Greenberg, David Malkin, Annie Huang, Eric Bouffet, Cynthia E. Hawkins, and Uri Tabori; The Hospital for Sick Children; Matthew Mistry, Patricia Rakopoulos, Rahul Krishnatry, Joshua Mangerel, Pawel Buczkowicz, Ana Guerreiro Stucklin, Doua Bakry, Adam Shlien, Mark Greenberg, David Malkin, Annie Huang, Eric Bouffet, Cynthia E. Hawkins, and Uri Tabori, University of Toronto; Jason D. Pole, Pediatric Oncology Group of Ontario, Toronto, Ontario; Jennifer Chan, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada; Pedro Castelo-Branco, Universidade do Algarve, Faro, Portugal; Keith L. Ligon, Dana-Farber/Boston Children's Cancer Center, Boston, MA. ^[1] Matthew Mistry, Nataliya Zhukova, Daniele Merico, Rahul Krishnatry, Mary Shago, James Stavropoulos, Noa Alon, Peter N. Ray, Vilma Navickiene, Joshua Mangerel, Marc Remke, Vijay Ramaswamy, Ana Guerreiro Stucklin, Martin Li, Edwin J. Young, Cindy Zhang, Pedro Castelo-Branco, Doua Bakry, Suzanne Laughlin, James T. Rutka, Peter B. Dirks, Michael D. Taylor, Mark Greenberg, David Malkin, Annie Huang, Eric Bouffet, Cynthia E. Hawkins, and Uri Tabori; The Hospital for Sick Children; Matthew Mistry, Patricia Rakopoulos, Rahul Krishnatry, Joshua Mangerel, Pawel Buczkowicz, Ana Guerreiro Stucklin, Doua Bakry, Adam Shlien, Mark Greenberg, David Malkin, Annie Huang, Eric Bouffet, Cynthia E. Hawkins, and Uri Tabori, University of Toronto; Jason D. Pole, Pediatric Oncology Group of Ontario, Toronto, Ontario; Jennifer Chan, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada; Pedro Castelo-Branco, Universidade do Algarve, Faro, Portugal; Keith L. Ligon, Dana-Farber/Boston Children's Cancer Center, Boston, MA. uri.tabori@sickkids.ca. ^[2]

医学主题词青少年(Adolescent);脑肿瘤(Brain Neoplasms);细胞转化, 肿瘤(Cell Transformation, Neoplastic);儿童(Child);儿童, 学龄前(Child, Preschool);染色质(Chromatin);周期素依赖激酶抑制剂p16(Cyclin-Dependent Kinase Inhibitor p16);疾病恶化(Disease Progression);女(雌)性(Female);随访研究(Follow-Up Studies);基因缺失(Gene Deletion);神经胶质瘤(Glioma);人类(Humans);婴儿(Infant);男(雄)性(Male);突变(Mutation);点突变(Point Mutation);原癌基因蛋白质B-raf(Proto-Oncogene Proteins B-raf);回顾性研究(Retrospective Studies);端粒(Telomere);治疗结果(Treatment Outcome)

DOI 10.1200/JCO.2014.58.3922

PMID 25667294

发布时间 2022-03-17

基金项目

P01 CA142536/CA/NCI NIH HHS/United States MOP-123268/Canadian Institutes of Health Research/Canada P01CA142536/CA/NCI NIH HHS/United States

检索历史清除

BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.

Journal of clinical oncology

相似文献

同项目论文

Journal of clinical oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.

Journal of clinical oncology

相似文献

同项目论文

Journal of clinical oncology

相关期刊

检索历史清除